Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;44(4):327-332.
doi: 10.1177/01632787211047932. Epub 2021 Sep 30.

A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection

N Kojima  1 , N K Shrestha  2 , J D Klausner  3
Affiliations

A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection

N Kojima et al. Eval Health Prof. 2021 Dec.

Abstract

We systematically reviewed studies to estimate the risk of SARS-CoV-2 reinfection among those previously infected with SARS-CoV-2. For this systematic review, we searched scientific publications on PubMed and MedRxiv, a pre-print server, through August 18, 2021. Eligible studies were retrieved on August 18, 2021. The following search term was used on PubMed: ((("Cohort Studies"[Majr]) AND ("COVID-19"[Mesh] OR "SARS-CoV-2"[Mesh])) OR "Reinfection"[Majr]) OR "Reinfection"[Mesh]. The following search term was used on MedRxiv: "Cohort Studies" AND "COVID-19" OR "SARS-CoV-2" AND "Reinfection". The search terms were broad to encompass all applicable studies. There were no restrictions on the date of publication. Studies that did not describe cohorts with estimates of the risk of SARS-CoV-2 reinfection among those with previous infection were excluded. Studies that included vaccinated participants were either excluded or limited to sub-groups of non-vaccinated individuals. To identify relevant studies with appropriate control groups, we developed the following criteria for studies to be included in the systematic analysis: (1) baseline polymerase chain reaction (PCR) testing, (2) a uninfected comparison group, (3) longitudinal follow-up, (4) a cohort of human participants, i.e. not a case report or case series, and (5) outcome determined by PCR. The review was conducted following PRISMA guidelines. We assessed for selection, information, and analysis bias, per PRISMA guidelines. We identified 1,392 reports. Of those, 10 studies were eligible for our systematic review. The weighted average risk reduction against reinfection was 90.4% with a standard deviation of 7.7% (p-value: <0.01). Protection against SARS-CoV-2 reinfection was observed for up to 10 months. Studies had potential information, selection, and analysis biases. The protective effect of prior SARS-CoV-2 infection on re-infection is high and similar to the protective effect of vaccination. More research is needed to characterize the duration of protection and the impact of different SARS-CoV-2 variants.

Keywords: COVID; COVID-19; SARS-CoV-2; immunity; natural immunity; prior infection; reinfection; vaccination; vaccine.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: N.K. has received consulting fees from Curative Inc. J.D.K. serves as Medical Director of Curative Inc.

Figures

Figure 1.
Figure 1.
PRISMA flow diagram for systematic reviews.
See this image and copyright information in PMC

References

    1. Abu-Raddad L. J., Chemaitelly H., Coyle P., Malek J. A., Ahmed A. A., Mohamoud Y. A., Younuskunju S., Ayoub H. H., Al Kanaani Z., Al Kuwari E., Butt A. A., Jeremijenko A., Kaleeckal A. H., Latif A. N., Shaik R. M., Abdul Rahim H. F., Nasrallah G. K., Yassine H. M., Al Kuwari M. G.…Bertollini R. (2021). SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine, 35, 100861. 10.1016/j.eclinm.2021.100861 - DOI - PMC - PubMed
    1. Addetia A., Crawford K. H. D., Dingens A., Zhu H., Roychoudhury P., Huang M. L., Jerome K. R., Bloom J. D., Greninger A. L. (2020). Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. Journal of Clinical Microbiology, 58(11). 10.1128/JCM.02107-20 - DOI - PMC - PubMed
    1. Breathnach A. S., Duncan C. J. A., Bouzidi K. E., Hanrath A. T., Payne B. A. I., Randell P. A., Habibi M. S., Riley P. A., Planche T. D., Busby J. S., Sudhanva M., Pallett S. J. C., Kelleher W. P. (2021). Prior COVID-19 protects against reinfection, even in the absence of detectable antibodies. Journal of Infection, 83(2), 237–279. 10.1016/j.jinf.2021.05.024 - DOI - PubMed
    1. Cavanaugh A., Spicer K., Thoroughman D., Glick C., Winter K. (2021). Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination—Kentucky, May–June 2021. Morbidity and Mortality Weekly Report (MMWR). 10.15585/mmwr.mm7032e1 - DOI - PMC - PubMed
    1. Christie A., Brooks J. T., Hicks L. A., Sauber-Schatz E. K., Yoder J. S., Honein M. A., Team C. C.-R. (2021). Guidance for implementing COVID-19 prevention strategies in the context of varying community transmission levels and vaccination coverage. Morbidity and Mortality Weekly Report (MMWR), 70(30), 1044–1047. 10.15585/mmwr.mm7030e2 - DOI - PMC - PubMed

Publication types